Hormone Planning Period

A guide to the planning period for new patients interested in gender-affirming hormone therapy.

The following is a guide to the planning period for trans and non-binary (TNB) patients who have reached Tanner Stage V in pubertal development and are interested in hormone therapy (for options for pubertal youth, please refer to the Endocrine Society Guidelines and this CMAJ article). It is more important that the tasks of the planning period are completed, rather than a certain number of visits logged or period of time elapsed.

The planning period is important for:

  • Establishing rapport with the patient
  • Ensuring the patient has all the information they need to start hormone therapy
  • Ensuring the patient feels prepared
  • Offering additional supports to the patient as needed

Patient History

TNB patients invariably experience some degree of minority stress, and many are exposed to gender-based interpersonal violence. Negative experiences in healthcare settings can further exacerbate the effects of this trauma. In addition to ensuring a gender-affirming approach to all patients, it is encouraged that providers be familiar with and practice trauma-informed care.

  • How would you like to be addressed? What name and pronouns would you like me to use?How would you like to be addressed? What name and pronouns would you like me to use?

Facilitate a trusting, open relationship by using respectful language.

  • Always refer to your patient by their chosen name and pronouns. If you are unsure, ask the patient how they would like to be addressed.
  • Check in with your patient regularly about changes to their name or pronouns, and encourage them to let you know if those change in the future.
  • When referring to a patient, use language that describes their present identity, not their sex assigned at birth.

  • How would you describe your gender identity? If prompting is needed: For example, some people identify as a man, transmasculine, genderqueer, etc.
  • Do you remember the time when you realized that your gender was different from the one you were assigned at birth? Or: Do you remember when you first started to see your gender as ______?
  • Can you tell me a bit about what’s happened since realizing this? If prompting is needed: Some people find this to be a difficult realization and may not feel comfortable to discuss it, other people are fortunate to have people in their life they feel safe talking with – what was it like for you?
  • Have you taken any steps to express your gender differently/to feel more comfortable in your gender? If prompting is needed: Some people ask others to use a different name and pronoun, or make changes to their hair or clothing styles.
  • If they have taken steps to express their gender differently: What was that like for you? How did that feel?

Source: Trans Care BC, Health Professionals Toolkit

General Medical Intake

This includes obtaining past records from previous provider(s), if this is a new patient.

Gender History

Speaking with clients about their history and experience with gender is not something healthcare providers are typically taught in training. However, it is an important part of getting to know a gender-diverse patient and informs the discussion around developing an individualized care plan. Reassure your patient that there are no “wrong answers” and no specific narrative the provider is looking to hear. Not all TNB people experience gender dysphoria or display gender diversity in childhood; TNB identities may emerge at any point in life.

Baseline Data

Focused Physical Exam

A focused physical exam is generally recommended prior to the initiation of hormone therapy. The exam should include screening for problems such as hypertension, obesity, and active liver disease which may increase the risks of hormone therapy.

A baseline breast exam (i.e., to assess for the presence of baseline gynecomastia) may be helpful for transfeminine patients, particularly those who may wish to pursue publicly-funded breast augmentation.*

*MOH funding for breast augmentation is restricted to those who experience no breast development after 12 months on estrogen.

Many trans patients have avoided medical care due to fear of mistreatment or stigmatization and may not have had routine screening. A discussion of the risks and benefits of a particular manoeuvre may be helpful. In some situations, an exam can be deferred or declined.

You can build rapport and increase a patient’s comfort by:

  • Carefully explaining to the patient ahead of time why the exam is essential to the patient’s health
  • Use neutral and inclusive terminology to avoid patient discomfort. If you are unsure, ask what terms your patient prefers.

Gendered terms may be uncomfortable or distressing for trans patients to hear. Try using neutral and inclusive terminology to avoid patient discomfort. If you are unsure, ask what terms your patient prefers.

Gendered Terms
Less Gendered Terms

Breasts

Chest

Vulva

External pelvic area

Vagina

Genital opening, frontal pelvic opening, internal canal

Uterus, ovaries

Reproductive organs, internal organs, estrogen producing tissue

Pap Smear

Cancer screening

Period, Menstruation

(Monthly) Bleeding

Testicles

Testosterone producing tissue, reproductive organs

Bra, panties, boxers, briefs

Underwear, under garments

Source: “If You Have It, Check It: Overcoming Barriers to Cervical Cancer Screening with Patients on the Female-to-Male Transgender Spectrum”. Jennifer Potter, MD, Sarah Peitzmeier, MSPH, Sari Reisner, ScD, MA, Ida Bernstein, Fenway Health. The National LGBT Health Education Center.

Vitals

Baseline measures include blood pressure, height and weight.

Bloodwork

Laboratory tests are used to investigate for existing health problems such as liver dysfunction, high cholesterol, or diabetes. If present, these conditions should ideally be managed prior to or concurrently with starting hormone therapy. The values will also provide a useful baseline to help with the future monitoring for endocrine changes. The measurement of hormone levels may reveal whether any exogenous hormones are being taken; any major irregularities could also indicate an intersex condition.

Baseline bloodwork summary for transfeminine and transmasculine patients

Bloodwork
Transfeminine
Transmasculine

CBC

✓

✓

ALT

✓

✓

Creatinine/Lytes

✓

HbA1c or Fasting Glucose

✓

✓

Lipid Profile

✓

✓

Total Testosterone

✓

✓

Estradiol

✓

Prolactin

✓

LH*

✓

Other**

Hep B, C

Hep B, C
Pregnancy Test (before first injection)

*Post-gonadectomy: Elevated LH in transmasculine individuals may have implications regarding bone mineral density (See Osteoporosis and BMD Screening)
**Consider HIV, syphilis, and other STI screening as indicated

Patient Education

Allow the patient to articulate their transition goals and expectations, and discuss whether those expectations are realistic. Physical changes from hormones can be slow; some secondary sex characteristics may take years to develop, and underlying body structure will not change. Providing estimated timelines for hormonal effects can be helpful, while emphasizing that response to therapy is highly individual. For more information, see the feminizing and masculinizing hormone therapy sections of this site.

Questions to open a conversation about realistic expectations:

  • What are your expectations around hormone therapy and transitioning?
  • How do you think taking hormones and transitioning will affect your relationships?
  • What do you think the impact might be on your work, school or community life?
  • What will you do if your gender transition doesn’t turn out as you had expected?
  • What changes are you most looking forward to? Are there any potential changes you are not sure about?
  • If you experience side effects, what will you do? Are there any potential side effects that you are concerned about?
  •  How do you feel about the irreversibility of some effects of hormones, including the possibility of permanent infertility? (This is more a concern in those with sperm than in those with eggs)

Source: Trans Care BC, Health Professionals Toolkit

Discuss the effects of hormone therapy on fertility with the patient. Feminizing hormone therapy reduces testicular volume and affects sperm motility and density, which may be irreversible. Masculinizing hormone therapy suppresses ovulation by reducing gonadotropin secretion; this effect is typically reversible after discontinuation, though recovery timelines are variable.1 Ask whether they hope to have a genetically-related child one day and, if so, whether they are interested in banking sperm or eggs.

Transfeminine Fertility Preservation Options

If a patient suspects they may wish to have genetically-related children in the future they should be advised to bank sperm prior to starting hormones. Sperm cryopreservation following ejaculation is the simplest and most reliable form of preservation, but other procedures, such as testicular sperm extraction (TESE) can be considered when ejaculation is overly burdensome or difficult. Patients may also attempt conception or undergo fertility preservation following the suspension of hormone therapy for three to six months, as testicular function may recover to a variable degree.

Transmasculine Fertility Preservation Options

While many transmasculine people have intentionally become pregnant after discontinuing testosterone to pursue pregnancy, patients may wish to consider postponing testosterone initiation if they want to become pregnant in the near future. Counselling regarding fertility preservation should occur prior to starting hormones. Ideally completed before hormone initiation, fertility preservation can also be performed after temporary or permanent discontinuation of testosterone. Fertility preservation involves cryopreservation of ova or embryos created via fertilization with sperm from a partner or donor. This involves harvesting of ova following ovarian stimulation through administration of female hormones, as well as multiple transvaginal ultrasounds and a transvaginal procedure to aspirate the ova. This often represents a substantial physical and psychological burden for transmasculine patients.

Discuss pregnancy risk and options for contraception with the patient. It’s important to have a discussion about sex and birth control.

Birth Control Options

Transfeminine patients should be cautioned regarding the need for birth control if sexually active with partners who may become pregnant, since hormonal impact on fertility in transfeminine patients is variable.

Testosterone is a teratogen – reliable contraception may be required depending on sexual practices.

Testosterone therapy should not be relied upon to prevent pregnancy even if amenorrhea is achieved. The patient must take precautions against becoming pregnant while taking it. Patients who are sexually active with people with sperm should be counselled on contraceptive options including:

  • Progesterone-only contraception
  • An intrauterine system/device (IUS/IUD); anecdotally, it may be easier to insert an IUS/IUD prior to initiating testosterone, due to the subsequent atrophic changes of the vaginal and cervical tissues2
  • Etonogestrel implant (Nexplanon); however, the common side effect of irregular spotting may limit its utility for menstrual cessation

If testosterone is initiated, the provider should check in with the patient periodically regarding their sexual behaviour and reiterate the necessary precautions should the patient become sexually active with people who produce sperm.

Gender transition is a significant life adjustment. As with any major stressor, the goal is to ensure patients have adequate supports to facilitate healthy coping.

Individual therapy with a trans-positive therapist may be beneficial for processing transition-related concerns and accessing psychological support. While not required for initiating gender-affirming hormone treatment, patients are encouraged to discuss their transition with family and friends, who will also be affected and may have their own reactions. A directory of providers experienced with 2SLGBTQ+ individuals is available through Rainbow Health Ontario.

Questions to open a conversation about psychosocial readiness:

  • Have you thought about how you will manage the changes in your appearance and gender expression at work or school?
  • Who has supported you along the way? If they have not spoken with anyone else yet: Who do you think might be supportive if you bring this up with them?
  • Have you done anything to prepare yourself for this step? If prompting is needed: Have you talked with any peers or asked friends or family for support? Done any reading or research?
  • Do you anticipate any challenges?
  • Some people find it helpful to have the support of a counsellor for either decision-making or ongoing support after beginning hormone therapy – does this sound like something you might be interested in?

Source: Trans Care BC, Health Professionals Toolkit

Discuss and ensure your patient demonstrates a good understanding of the potential benefits, risks and side effects of hormone therapy. Discuss the different treatment options. This information, including formulations and recommended dosages, can be found in the feminizing and masculinizing hormone therapy sections of this site.

Does the patient possess capacity to consent?

As with any other medical intervention, patients must demonstrate an understanding of the risks and benefits of hormone treatment. Obtaining informed consent is a process that primary care providers engage in daily, and when prescribing hormones to TNB patients, the same basic principles apply. Questions may arise around capacity to consent in individuals with cognitive or developmental disabilities, significant mental health and substance use challenges, or younger patients. Since there is no specific age determining when an individual is eligible to provide consent for medical interventions in Canada, it is determined on a case-by-case basis and at the discretion of the provider.

Discuss the potential costs of hormone therapy and other gender-affirming care. Costs for medications (for those without drug coverage) vary and are listed in the feminizing and masculinizing hormone therapy sections. Certain formulations are covered for patients on the Ontario Drug Benefit (ODB) program. For instance, injectable testosterone is funded by the ODB program for gender affirmation with an Exceptional Access Program (EAP) request. For more details and related forms, visit our Referrals & Advocacy page.

Fertility preservation is not presently covered by OHIP. Currently, some hospital-based clinics may offer a discounted rate for medically necessary gamete preservation and subsequent fertility treatment, such as in the case of gender transition. If indicated, referral to a fertility clinic should be initiated early in the hormone planning period as this process takes time. Care should be taken to refer patients for fertility services at centres that have experience working with trans and non-binary people whenever possible.

Hair removal is relevant especially to transfeminine patients since hormone administration may slow the growth of hair, but not substantially reduce the amount of facial or body hair. As such, laser treatments and/or electrolysis are often required. These services are not presently covered by OHIP and it can be a challenge to find a provider who is both sensitive to the trans patient and able to work within fixed budgets. Permanently eliminating the bulk of facial hair may cost up to several thousand dollars and this should be discussed up-front and considered in the timeline of the patient’s medical and social transition. A directory of providers experienced with 2SLGBTQ+ individuals is available through Rainbow Health Ontario.

Your patient may seek assistance from you in order to access services and supports, such as changing sex designation on an Ontario birth registration or driver’s license.

Visit our Referrals & Advocacy page and Rainbow Health Ontario’s Trans Health Knowledge Base for more information.

Risk Management

Have precautions been optimally managed or is a management plan in place?

Each hormone will have its own specific considerations and precautions which are explained in more detail in the feminizing and masculinizing hormone therapy sections. However, it is worthwhile to address general considerations and precautions with hormone use.

Denying access to hormones can do much more harm than the possible risks of treatment. With an informed-consent approach (support, education and consent) many providers will initiate hormones with individuals with higher risk profiles when it increases their quality of life/chance of survival greatly.

Lifestyle Considerations

Starting hormone therapy and the prospect of aligning one’s body with an internal sense of gender can create an opportunity for patients to develop a new relationship with their body and initiate positive lifestyle changes. We have often seen this time of transition inspire lasting health improvements.

Smoking and obesity increase the risks associated with hormone therapy. It is worthwhile for the provider and patient to work together to reduce these risks where possible, with the understanding that this is not always feasible before starting treatment and that a harm reduction approach may be necessary. Substance use disorders, whether involving alcohol, street drugs or prescription medications, may introduce additional risks that should be considered.

Mental Health Considerations

TNB patients invariably experience some degree of minority stress. They have a higher prevalence of stress-related mental health conditions, such as depression, anxiety and substance use disorders. The presence of mental health concerns does not preclude access to hormone therapy; rather, according to WPATH, these concerns should ideally be “reasonably well controlled prior to or concurrently with hormone therapy.” There is no convincing evidence that hormone therapy causes or worsens mental health conditions; in fact, many studies have shown consistent improvements in psychological functioning. Nonetheless, caution may be prudent in patients with bipolar disorder or psychotic disorders, particularly when these are sub-optimally managed. Primary care providers can help patients optimize their mental health in preparation for and throughout medical transition.

Suggested elements for periodic review by Collaborative MD and Nursing Team
  • Screen for depressive symptoms (including suicidality), anxiety disorders, and other mental health concerns
  • Inquire re: current experience of gender dysphoria and body image
  • Screen for disordered eating
  • Assess patient interest in surgical treatments if not previously undergone
  • Inquire re: libido/changes in libido

For patients with complex, severe or poorly controlled mental health conditions, a referral to a specialized centre or to a psychiatrist with experience working with TNB patients can be helpful.

Although acute suicidality has previously been considered a contraindication to hormone therapy, particularly testosterone, there may be cases where a patient at significant risk of suicide but able to provide informed consent may benefit greatly from starting hormones. This may be especially true when intense gender dysphoria is the main source of psychological distress.

We suggest these situations be approached on a case-by-case basis, weighing the risks and benefits of hormone therapy in relation to the patient’s mental health. In some cases, the best course may be to start low-dose therapy while implementing suicide risk reduction strategies, such as establishing a crisis plan and connecting the patient with additional mental health support. If a patient is experiencing a major depressive episode, pharmacotherapy should be discussed.

Differential Diagnosis

Rule out other possible diagnoses (e.g., schizophrenia and other psychotic disorders, dissociative disorder and body dysmorphic disorder). Such diagnoses are rarely found to be underlying the desire for gender-affirming treatment, but can occur and thus should be ruled out. If the presentation is unclear, it is appropriate to obtain the opinion of a psychiatrist who is experienced in working with TNB people if possible.

Ensure there is no evidence of an intersex condition.

Does the patient meet the criteria for gender dysphoria/gender incongruence?

Harm Reduction

Fast-Tracking Through the Planning Period

Provision of hormone treatment may be undertaken, in some cases, without completing all of the usual tasks of the planning period. Situations that may warrant a degree of ‘fast-tracking’ through the planning period include:

  • A patient who is already using hormones without a prescription
  • A patient who has marked distress regarding their gender presentation
  • The patient’s medical and/or gender history are well known prior to the patient seeking hormone therapy
  • If another knowledgeable provider has recently performed part or all of the assessment and the associated records are available for review or a conversation with the prior provider can be arranged, all tasks of the assessment period need not be repeated
  1. Moravek MB, Kinnear HM, George J, et al. Impact of exogenous testosterone on reproduction in transgender men. Endocrinology. 2020;161(3):bqaa014.
  2. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000 May 15;61(10):3090–6. PMID: 10839558.